Sponsors
The bill aims to lower Medicare and Medicaid drug costs by benchmarking certain U.S. payments to lower international prices, delivering likely near-term savings for beneficiaries and taxpayers but risking reduced drug availability, added administrative complexity, and potential long-term impacts on pharmaceutical innovation.
Medicare and Medicaid beneficiaries (and patients who use covered drugs) would likely face lower prices and reduced out-of-pocket costs because MFN ties certain U.S. drug payments to lower net prices in eight reference countries.
The federal government and taxpayers may save on Medicare/Medicaid drug spending over the 5-year model period if MFN prices reduce program outlays.
Manufacturers will face clearer reporting requirements, improving CMS's ability to calculate fair international-comparison prices and increasing program transparency and enforceability.
Manufacturers may respond to lower MFN revenues by raising list prices, limiting supply, restricting distribution, delaying U.S. launches, or withdrawing products from the U.S. market, risking reduced drug availability for patients and hospitals.
If MFN-driven price reductions materially lower manufacturer revenues, long-term investment in pharmaceutical R&D could decline, potentially slowing development of new drugs.
The policy creates added administrative and compliance burdens—on manufacturers to report international net-price data and on CMS to collect and verify it—and the exemption process (e.g., through April 1, 2029) adds complexity that could undermine uniform implementation.
Based on analysis of 2 sections of legislative text.
Requires CMMI to test a Most Favored Nations drug-pricing model from Jan 1, 2029, making specified manufacturers offer MFN prices (second-lowest net price among eight reference countries) for covered drugs.
Introduced March 5, 2026 by Dan Meuser · Last progress March 5, 2026
Requires the Center for Medicare and Medicaid Innovation (CMMI) to include and test a Most Favored Nations (MFN) drug-pricing model beginning January 1, 2029. Under the model, specified drug manufacturers must make a ‘‘most-favored-nation price’’ available for covered drugs — defined as the second-lowest applicable net price among eight reference countries — to eligible beneficiaries, dispensers, and providers, and must report data needed to calculate those prices. The bill allows the Secretary to temporarily suspend MFN requirements for a manufacturer’s drug until April 1, 2029 if the manufacturer is likely to enter a negotiated “covered agreement” with the Secretary by year-end 2028; covered agreements must be executed by December 31, 2028, include commitments to boost U.S. manufacturing, and be reported to designated congressional committees. The MFN model would run for five years and the amendment adds detailed definitions and reporting obligations to support implementation.